CDT Equity Inc. Files 8-K on Material Agreement & Equity Sales

Ticker: CDTTW · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1896212

Cdt Equity Inc. 8-K Filing Summary
FieldDetail
CompanyCdt Equity Inc. (CDTTW)
Form Type8-K
Filed DateDec 12, 2025
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $7,000,000
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, filing

TL;DR

CDT Equity Inc. filed an 8-K detailing a material agreement and equity sales, effective Dec 8, 2025.

AI Summary

CDT Equity Inc. filed an 8-K on December 12, 2025, reporting on events that occurred on December 8, 2025. The filing indicates an entry into a material definitive agreement, unregistered sales of equity securities, and includes financial statements and exhibits. The company, formerly known as Conduit Pharmaceuticals Inc. and Murphy Canyon Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This 8-K filing signals significant corporate activity for CDT Equity Inc., including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce complexities and potential risks related to the terms and implications of these transactions.

Key Players & Entities

  • CDT Equity Inc. (company) — Registrant
  • Conduit Pharmaceuticals Inc. (company) — Former company name
  • Murphy Canyon Acquisition Corp. (company) — Former company name
  • December 8, 2025 (date) — Earliest event reported
  • December 12, 2025 (date) — Filing date

FAQ

What was the nature of the material definitive agreement entered into by CDT Equity Inc. on December 8, 2025?

The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in the provided text.

What type of equity securities were sold by CDT Equity Inc. on December 8, 2025?

The filing mentions 'Unregistered Sales of Equity Securities' but does not specify the exact type of securities sold in the provided text.

When was CDT Equity Inc. formerly known as Conduit Pharmaceuticals Inc. and Murphy Canyon Acquisition Corp.?

CDT Equity Inc. was formerly known as Conduit Pharmaceuticals Inc. after September 22, 2023, and was formerly known as Murphy Canyon Acquisition Corp. after November 30, 2021.

What is the Standard Industrial Classification (SIC) code for CDT Equity Inc.?

The SIC code for CDT Equity Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the business address of CDT Equity Inc.?

The business address of CDT Equity Inc. is 4851 Tamiami Trail North, Suite 200, Naples, FL 34103.

Filing Stats: 998 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-12-12 16:15:52

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
  • $7,000,000 — tive Officer for a settlement amount of $7,000,000 that was satisfied through the issuance

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Pre-Funded Warrant entered into by and between the Company and Corvus on December 8, 2025. 10.1 Sale and Purchase Agreement, dated December 8, 2025, by and between the Company and Corvus. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CDT EQUITY INC. December 12, 2025 By: /s/ Andrew Regan Name: Andrew Regan Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.